2
|
Lapaille M, Escobar-Ramírez A, Degand H, Baurain D, Rodríguez-Salinas E, Coosemans N, Boutry M, Gonzalez-Halphen D, Remacle C, Cardol P. Atypical subunit composition of the chlorophycean mitochondrial F1FO-ATP synthase and role of Asa7 protein in stability and oligomycin resistance of the enzyme. Mol Biol Evol 2010; 27:1630-44. [PMID: 20156838 DOI: 10.1093/molbev/msq049] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
In yeast, mammals, and land plants, mitochondrial F(1)F(O)-ATP synthase (complex V) is a remarkable enzymatic machinery that comprises about 15 conserved subunits. Peculiar among eukaryotes, complex V from Chlamydomonadales algae (order of chlorophycean class) has an atypical subunit composition of its peripheral stator and dimerization module, with nine subunits of unknown evolutionary origin (Asa subunits). In vitro, this enzyme exhibits an increased stability of its dimeric form, and in vivo, Chlamydomonas reinhardtii cells are insensitive to oligomycins, which are potent inhibitors of proton translocation through the F(O) moiety. In this work, we showed that the atypical features of the Chlamydomonadales complex V enzyme are shared by the other chlorophycean orders. By biochemical and in silico analyses, we detected several atypical Asa subunits in Scenedesmus obliquus (Sphaeropleales) and Chlorococcum ellipsoideum (Chlorococcales). In contrast, complex V has a canonical subunit composition in other classes of Chlorophytes (Trebouxiophyceae, Prasinophyceae, and Ulvophyceae) as well as in Streptophytes (land plants), and in Rhodophytes (red algae). Growth, respiration, and ATP levels in Chlorophyceae were also barely affected by oligomycin concentrations that affect representatives of the other classes of Chlorophytes. We finally studied the function of the Asa7 atypical subunit by using RNA interference in C. reinhardtii. Although the loss of Asa7 subunit has no impact on cell bioenergetics or mitochondrial structures, it destabilizes in vitro the enzyme dimeric form and renders growth, respiration, and ATP level sensitive to oligomycins. Altogether, our results suggest that the loss of canonical components of the complex V stator happened at the root of chlorophycean lineage and was accompanied by the recruitment of novel polypeptides. Such a massive modification of complex V stator features might have conferred novel properties, including the stabilization of the enzyme dimeric form and the shielding of the proton channel. In these respects, we discuss an evolutionary scenario for F(1)F(O)-ATP synthase in the whole green lineage (i.e., Chlorophyta and Streptophyta).
Collapse
Affiliation(s)
- Marie Lapaille
- Genetics of Microorganisms, Department of Life Sciences, Université de Liège, Belgium
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Seyda A, Newbold RF, Hudson TJ, Verner A, MacKay N, Winter S, Feigenbaum A, Malaney S, Gonzalez-Halphen D, Cuthbert AP, Robinson BH. A novel syndrome affecting multiple mitochondrial functions, located by microcell-mediated transfer to chromosome 2p14-2p13. Am J Hum Genet 2001; 68:386-96. [PMID: 11156534 PMCID: PMC1235272 DOI: 10.1086/318196] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2000] [Accepted: 11/28/2000] [Indexed: 11/03/2022] Open
Abstract
We have studied cultured skin fibroblasts from three siblings and one unrelated individual, all of whom had fatal mitochondrial disease manifesting soon after birth. After incubation with 1 mM glucose, these four cell strains exhibited lactate/pyruvate ratios that were six times greater than those of controls. On further analysis, enzymatic activities of the pyruvate dehydrogenase complex, the 2-oxoglutarate dehydrogenase complex, NADH cytochrome c reductase, succinate dehydrogenase, and succinate cytochrome c reductase were severely deficient. In two of the siblings the enzymatic activity of cytochrome oxidase was mildly decreased (by approximately 50%). Metabolite analysis performed on urine samples taken from these patients revealed high levels of glycine, leucine, valine, and isoleucine, indicating abnormalities of both the glycine-cleavage system and branched-chain alpha-ketoacid dehydrogenase. In contrast, the activities of fibroblast pyruvate carboxylase, mitochondrial aconitase, and citrate synthase were normal. Immunoblot analysis of selected complex III subunits (core 1, cyt c(1), and iron-sulfur protein) and of the pyruvate dehydrogenase complex subunits revealed no visible changes in the levels of all examined proteins, decreasing the possibility that an import and/or assembly factor is involved. To elucidate the underlying molecular defect, analysis of microcell-mediated chromosome-fusion was performed between the present study's fibroblasts (recipients) and a panel of A9 mouse:human hybrids (donors) developed by Cuthbert et al. (1995). Complementation was observed between the recipient cells from both families and the mouse:human hybrid clone carrying human chromosome 2. These results indicate that the underlying defect in our patients is under the control of a nuclear gene, the locus of which is on chromosome 2. A 5-cM interval has been identified as potentially containing the critical region for the unknown gene. This interval maps to region 2p14-2p13.
Collapse
Affiliation(s)
- Agnieszka Seyda
- Metabolism Research Programme, Research Institute and Division of Clinical Genetics, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Department of Biology and Biochemistry, Brunel University, Uxbridge, UK, Montréal General Hospital, Montréal; Medical Genetics/Metabolism, Valley Children’s Hospital, Fresno, CA; Garvin Institute of Medical Research, Darlinghurst, Australia; Departamento de Bioenergetica, Universidad Nacional Autonoma de Mexico, Mexico City; and Division of Medical and Molecular Genetics, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London
| | - Robert F. Newbold
- Metabolism Research Programme, Research Institute and Division of Clinical Genetics, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Department of Biology and Biochemistry, Brunel University, Uxbridge, UK, Montréal General Hospital, Montréal; Medical Genetics/Metabolism, Valley Children’s Hospital, Fresno, CA; Garvin Institute of Medical Research, Darlinghurst, Australia; Departamento de Bioenergetica, Universidad Nacional Autonoma de Mexico, Mexico City; and Division of Medical and Molecular Genetics, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London
| | - Thomas J. Hudson
- Metabolism Research Programme, Research Institute and Division of Clinical Genetics, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Department of Biology and Biochemistry, Brunel University, Uxbridge, UK, Montréal General Hospital, Montréal; Medical Genetics/Metabolism, Valley Children’s Hospital, Fresno, CA; Garvin Institute of Medical Research, Darlinghurst, Australia; Departamento de Bioenergetica, Universidad Nacional Autonoma de Mexico, Mexico City; and Division of Medical and Molecular Genetics, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London
| | - Andrei Verner
- Metabolism Research Programme, Research Institute and Division of Clinical Genetics, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Department of Biology and Biochemistry, Brunel University, Uxbridge, UK, Montréal General Hospital, Montréal; Medical Genetics/Metabolism, Valley Children’s Hospital, Fresno, CA; Garvin Institute of Medical Research, Darlinghurst, Australia; Departamento de Bioenergetica, Universidad Nacional Autonoma de Mexico, Mexico City; and Division of Medical and Molecular Genetics, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London
| | - Neviana MacKay
- Metabolism Research Programme, Research Institute and Division of Clinical Genetics, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Department of Biology and Biochemistry, Brunel University, Uxbridge, UK, Montréal General Hospital, Montréal; Medical Genetics/Metabolism, Valley Children’s Hospital, Fresno, CA; Garvin Institute of Medical Research, Darlinghurst, Australia; Departamento de Bioenergetica, Universidad Nacional Autonoma de Mexico, Mexico City; and Division of Medical and Molecular Genetics, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London
| | - Susan Winter
- Metabolism Research Programme, Research Institute and Division of Clinical Genetics, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Department of Biology and Biochemistry, Brunel University, Uxbridge, UK, Montréal General Hospital, Montréal; Medical Genetics/Metabolism, Valley Children’s Hospital, Fresno, CA; Garvin Institute of Medical Research, Darlinghurst, Australia; Departamento de Bioenergetica, Universidad Nacional Autonoma de Mexico, Mexico City; and Division of Medical and Molecular Genetics, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London
| | - Annette Feigenbaum
- Metabolism Research Programme, Research Institute and Division of Clinical Genetics, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Department of Biology and Biochemistry, Brunel University, Uxbridge, UK, Montréal General Hospital, Montréal; Medical Genetics/Metabolism, Valley Children’s Hospital, Fresno, CA; Garvin Institute of Medical Research, Darlinghurst, Australia; Departamento de Bioenergetica, Universidad Nacional Autonoma de Mexico, Mexico City; and Division of Medical and Molecular Genetics, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London
| | - Suzann Malaney
- Metabolism Research Programme, Research Institute and Division of Clinical Genetics, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Department of Biology and Biochemistry, Brunel University, Uxbridge, UK, Montréal General Hospital, Montréal; Medical Genetics/Metabolism, Valley Children’s Hospital, Fresno, CA; Garvin Institute of Medical Research, Darlinghurst, Australia; Departamento de Bioenergetica, Universidad Nacional Autonoma de Mexico, Mexico City; and Division of Medical and Molecular Genetics, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London
| | - Diego Gonzalez-Halphen
- Metabolism Research Programme, Research Institute and Division of Clinical Genetics, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Department of Biology and Biochemistry, Brunel University, Uxbridge, UK, Montréal General Hospital, Montréal; Medical Genetics/Metabolism, Valley Children’s Hospital, Fresno, CA; Garvin Institute of Medical Research, Darlinghurst, Australia; Departamento de Bioenergetica, Universidad Nacional Autonoma de Mexico, Mexico City; and Division of Medical and Molecular Genetics, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London
| | - Andrew P. Cuthbert
- Metabolism Research Programme, Research Institute and Division of Clinical Genetics, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Department of Biology and Biochemistry, Brunel University, Uxbridge, UK, Montréal General Hospital, Montréal; Medical Genetics/Metabolism, Valley Children’s Hospital, Fresno, CA; Garvin Institute of Medical Research, Darlinghurst, Australia; Departamento de Bioenergetica, Universidad Nacional Autonoma de Mexico, Mexico City; and Division of Medical and Molecular Genetics, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London
| | - Brian H. Robinson
- Metabolism Research Programme, Research Institute and Division of Clinical Genetics, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Department of Biology and Biochemistry, Brunel University, Uxbridge, UK, Montréal General Hospital, Montréal; Medical Genetics/Metabolism, Valley Children’s Hospital, Fresno, CA; Garvin Institute of Medical Research, Darlinghurst, Australia; Departamento de Bioenergetica, Universidad Nacional Autonoma de Mexico, Mexico City; and Division of Medical and Molecular Genetics, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Hospital, London
| |
Collapse
|